These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease. Naoi M; Maruyama W Adv Neurol; 1999; 80():259-64. PubMed ID: 10410730 [No Abstract] [Full Text] [Related]
6. Neurosteroid and neurotransmitter alterations in Parkinson's disease. di Michele F; Luchetti S; Bernardi G; Romeo E; Longone P Front Neuroendocrinol; 2013 Apr; 34(2):132-42. PubMed ID: 23563222 [TBL] [Abstract][Full Text] [Related]
7. Brain neurotransmitters and neuropeptides in Parkinson's disease. Rinne UK; Rinne JO; Rinne JK; Laakso K; Lönnberg P Acta Physiol Pharmacol Latinoam; 1984; 34(3):287-99. PubMed ID: 6099688 [TBL] [Abstract][Full Text] [Related]
8. [Functional morphology of mediator systems of the brain]. Otellin VA Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(1):54-8. PubMed ID: 9505409 [No Abstract] [Full Text] [Related]
9. The use of PET in Parkinson's disease. Shinotoh H; Calne DB Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856 [TBL] [Abstract][Full Text] [Related]
10. [Involuntary movement and neurotransmitter systems]. Ogawa N Nihon Rinsho; 1993 Nov; 51(11):2811-5. PubMed ID: 7903985 [TBL] [Abstract][Full Text] [Related]
11. Actions of levodopa and dopamine in the central nervous system. Sourkes TL JAMA; 1971 Dec; 218(13):1909-11. PubMed ID: 4398939 [No Abstract] [Full Text] [Related]
12. Autoradiographic distributions of neurotransmitter receptors in the human brains of Parkinson's disease and primate models of MPTP-induced parkinsonism. Kito S; Miyoshi R; Mizuno K; Nitta K; Matsubayashi H; Yamamura Y; Tahara E Adv Neurol; 1987; 45():159-65. PubMed ID: 2881441 [No Abstract] [Full Text] [Related]
13. The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role? Agid Y; Graybiel AM; Ruberg M; Hirsch E; Blin J; Dubois B; Javoy-Agid F Adv Neurol; 1990; 53():83-100. PubMed ID: 1978522 [No Abstract] [Full Text] [Related]
14. Neuronal circuits and physiological roles of the basal ganglia in terms of transmitters, receptors and related disorders. Yamada K; Takahashi S; Karube F; Fujiyama F; Kobayashi K; Nishi A; Momiyama T J Physiol Sci; 2016 Nov; 66(6):435-446. PubMed ID: 26979514 [TBL] [Abstract][Full Text] [Related]
15. Pathophysiology and management of idiopathic Parkinson's disease. Lusis SA J Neurosci Nurs; 1997 Feb; 29(1):24-31. PubMed ID: 9067850 [TBL] [Abstract][Full Text] [Related]
16. Biochemistry of Parkinson's disease 28 years later: a critical review. Agid Y; Cervera P; Hirsch E; Javoy-Agid F; Lehericy S; Raisman R; Ruberg M Mov Disord; 1989; 4 Suppl 1():S126-44. PubMed ID: 2566912 [No Abstract] [Full Text] [Related]
18. Involvement of transmitter systems in neuropsychiatric diseases. Hartmann J; Künig G; Riederer P Acta Neurol Scand Suppl; 1993; 146():18-21. PubMed ID: 8101412 [TBL] [Abstract][Full Text] [Related]
19. [The physiopathology of the basal ganglia and the etiopathogenesis of Parkinson's diseases]. Stefanache F; Pendefunda L; Prodan R; Pendefunda G Rev Med Chir Soc Med Nat Iasi; 1989; 93(1):145-54. PubMed ID: 2573122 [No Abstract] [Full Text] [Related]
20. Type B monoamine oxidase and neurotoxins. Naoi M; Maruyama W Eur Neurol; 1993; 33 Suppl 1():31-7. PubMed ID: 8375430 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]